Valuation: Axsome Therapeutics, Inc.

Market Cap 12.81B 11.22B 10.35B 9.56B 18.13B 1,222B 18.43B 124B 48.42B 602B 48.1B 47.05B 2,071B P/E 2026 *
-123x
P/E 2027 * 43.4x
Enterprise Value 12.7B 11.13B 10.26B 9.48B 17.97B 1,211B 18.27B 123B 48.01B 596B 47.68B 46.65B 2,053B EV / Sales 2026 *
12.9x
EV / Sales 2027 * 7.77x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-6.09%
1 week-3.63%
Current month-4.48%
1 month-5.09%
3 months+31.27%
6 months+32.22%
Current year+28.01%
1 week 230.14
Extreme 230.1401
252.6
1 month 230.14
Extreme 230.1401
260.19
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 12/01/2012
Director of Finance/CFO 51 16/05/2018
Chief Operating Officer 42 01/04/2014
Director TitleAgeSince
Chairman 57 12/01/2012
Director/Board Member 64 01/12/2014
Director/Board Member 58 01/12/2014
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

Chief Executive Officer

148,998 0.2895%
06-11Sell

Director

-286 0.0006%
06-10Sell

Director

-300 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-6.09%-3.63%+111.14%+217.84% 12.81B
-0.51%+2.26%+18.72%-5.52% 67.96B
-5.16%-10.39%+39.22%+202.66% 54.4B
-2.10%+4.37%-49.58%-53.96% 41.74B
+5.28%+39.50%+39.50%+39.50% 40.63B
-10.83%-16.54%+99.15%-44.54% 30.38B
+0.12%-4.47%+47.16%-29.27% 29.37B
-1.53%+0.94%+65.92%+88.58% 23.68B
+3.88%+5.10%+9.06%+196.53% 19.15B
-4.75%+10.47%+85.63%+394.76% 17.68B
Average -0.88%+1.34%+46.59%+100.66% 33.78B
Weighted average by Cap. -0.73%+0.44%+35.56%+69.33%

Financials

2026 *2027 *
Net sales 981M 860M 793M 733M 1.39B 93.59B 1.41B 9.47B 3.71B 46.09B 3.68B 3.6B 159B 1.6B 1.4B 1.29B 1.19B 2.26B 152B 2.3B 15.43B 6.04B 75.07B 6B 5.87B 258B
Net income -106M -92.45M -85.24M -78.77M -149M -10.06B -152M -1.02B -399M -4.96B -396M -388M -17.06B 317M 278M 256M 237M 449M 30.27B 457M 3.06B 1.2B 14.91B 1.19B 1.17B 51.31B
Net Debt -111M -96.98M -89.42M -82.63M -157M -10.56B -159M -1.07B -418M -5.2B -416M -407M -17.9B -394M -345M -318M -294M -557M -37.56B -567M -3.8B -1.49B -18.49B -1.48B -1.45B -63.67B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
09/07/26 $248.95 +1.38% 621,739
08/07/26 $245.57 -1.68% 769,421
07/07/26 $249.76 +2.95% 1,055,991
06/07/26 $242.60 -0.70% 842,382
02/07/26 $244.31 +1.52% 854,306
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
248.95USD
Average target price
276.56USD
Spread / Average Target
+11.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock